Elise Ballard, NP
Family · Merrillville, INNPI 1275385361
Payments from drug & device makers
Across 116 payments — averaging $86.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Calliditas Therapeutics US Inc.$3K
- Otsuka America Pharmaceutical, Inc.$362
- AstraZeneca$348
- Ardelyx, Inc.$254
- Amgen$231
- plus $956 from 11 others
What the payments were for
- Consulting fees$6,01960%
- Travel & lodging$1,03310%
- Food & beverage$2,95029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $4,469 |
| Calliditas Therapeutics US Inc. | 14 | $3,382 |
| Otsuka America Pharmaceutical, Inc. | 19 | $362 |
| AstraZeneca(2 entities) | 9 | $348 |
| Ardelyx, Inc. | 14 | $254 |
| Amgen | 8 | $231 |
| Travere Therapeutics, Inc. | 13 | $207 |
| Akebia Therapeutics Inc | 3 | $164 |
| Fresenius USA Marketing, Inc. | 7 | $150 |
| Novo Nordisk | 1 | $114 |
| Lilly USA, LLC | 5 | $101 |
| Bayer | 2 | $61 |
| Vifor Pharma, Inc. | 2 | $40 |
| OPKO Pharmaceuticals, LLC | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Avyxa Pharma, LLC | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,002 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 21 | $5,202 |
| Carvedilol | 19 | $176 |
Paid to pharmacies, not to this prescriber.
Other family in Merrillville
- Mary HoffmanMerrillville$19K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.